Breakthrough may lead to anti-stroke vaccine

EU-funded scientists have discovered that the presence of low levels of a type of antibody in the immune system increases the chance of having a stroke, one of the leading causes of death worldwide. The finding, published in the journal Stroke, signals hope the development of a vaccine that can activate the body's natural defences against the condition.

The breakthrough is part of CVDIMMUNE (Immunomodulation and autoimmunity in cardiovascular disease and atherosclerosis), a project funded EUR 2.7 million under the 'Life sciences, genomics and biotechnology for health' Thematic area of the Sixth Framework Programme (FP6).

In the past, researchers from Karolinska Institutet in Sweden (the project's coordinating institution) were able to prove that the presence of high levels of an antibody, known as anti-PC, in the human body's immune system reduced the risk of arteriosclerosis. Arteriosclerosis occurs when plaque builds up on blood vessel walls. These plaques can rupture and develop into a blood clot. Atherosclerosis, which is a form of arteriosclerosis, is the most common cause of cardiovascular disease.

In the current study, the CVDIMMUNE team turned their attention to strokes, and discovered a similar outcome; people with low anti-PC levels were at an increased the risk of stroke. Lower levels of these natural antibodies, which could be the result of an unhealthy immune system, can therefore contribute to the onset of both arteriosclerosis and stroke.

The research, which involved a comparison study of 227 first-time stroke victims with 445 controls over a 13-year period (between 1985 and 1999), also demonstrated that the link between low anti-PC levels and stroke risk was particularly strong for women.

The results have opened the door to several possibilities. Measurements of anti-PC could now be used by doctors to identify those who are at greater risk of stroke, such as immunodeficient individuals. Likewise, the potential now exists for novel modes of treatment, such as immunotherapies.

Head of the study, Professor Johan Frostegård, said: "We're now examining the possibility of developing new immunological treatments for arteriosclerosis and stroke, either in the form of a vaccine to stimulate the immune defence or immunisation through the injection of antibodies."

The World Health Organization (WHO) estimates that 15 million people across the world suffer a stroke ever year. One third of these people die, and an additional third are left with some form of permanent disability. High blood pressure is believed to be the main culprit, contributing to almost 13 million of these strokes.

In Europe, the WHO estimates that strokes are responsible, on average, for 650,000 deaths every year. Quit-smoking campaigns and efforts focused on lowering blood pressure have helped reduce the incidence of stroke in developed countries. Due to the advent of an ageing population, however, the threat of stroke remains high in these countries.

Copyright ©European Communities, 2010
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

New strategy to treat Parkinson's disease

Northwestern Medicine scientists have used patient-derived neurons to develop and test a new strategy to treat Parkinson's disease by mitigating the effects of harmful ge...

AI could offer warnings about serious side effects…

The more medications a patient takes, the greater the likelihood that interactions between those drugs could trigger negative side effects, including long-term organ dama...

OPKO and Pfizer announce positive Phase 3 top-line…

OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with g...

Trastuzumab deruxtecan granted FDA Priority Review…

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics Lice...

The Bristol-Myers Squibb-Pfizer Alliance and Fitbi…

The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of a...

Nplate® (romiplostim) now approved for earlier use…

Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim...

Novartis announces that Jakavi® (ruxolitinib) meet…

Novartis today announced positive topline results from the Phase III REACH2 study evaluating Jakavi® (ruxolitinib) in patients with steroid-refractory acute graft-versus-...

Bayer launches LifeHub UK focused on artificial in…

Bayer launched LifeHub UK to accelerate and optimize disease detection and data-driven drug discovery by developing artificial-intelligence-enabled imaging solutions. The...

Amgen recommends rejection of 'mini-tender' offer …

Amgen (NASDAQ:AMGN) today announced that it has been notified of an unsolicited "mini-tender" offer dated Oct. 11, 2019, made by TRC Capital Corporation, a private Canadi...

Antibody-based eye drops show promise for treating…

Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodi...

First entirely digital clinical trial encourages p…

As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new s...

Abbott and Omada Health partner to offer integrate…

Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) ...